Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. Anti-Nivolumab Antibody (6G5H2E6) [Biotin], mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Nivolumab.
Klonalität:
Monoclonal
Klon-Bezeichnung:
[6G5H2E6]
Reinheit:
Protein A chromatography
Formulierung:
Purified
Application Verdünnung:
ELISA detection: 0.01-0.1 µg/ml
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
